局部进展期或晚期胃癌的免疫检查点抑制剂治疗现况及进展

田 青怡, 迪　 吉*
青海大学附属医院

摘要


部分胃癌患者在确诊时已经是进展期或晚期，此时通常已经错过了根治性手术的时机，只能进行化疗或靶
向治疗。然而，由于治疗无效或多重耐药，部分晚期胃癌患者的预后较差。随着对肿瘤微环境的认识和研究的深入，
免疫疗法被应用于胃癌的治疗。免疫疗法是指通过诱导人体内的免疫反应来杀伤癌细胞。与传统疗法相比，免疫疗
法（如免疫检查点抑制剂（ICI）、过继细胞疗法和嵌合抗原受体（CAR）T疗法）显示出强大的疗效和对不良反应
的可耐受性。其中，免疫检查点抑制剂在局部进展期或晚期胃癌的应用最为广泛且效果较好。本文就局部进展期或
晚期胃癌的免疫检查点抑制剂治疗现况及进展进行综述。

关键词


免疫检查点抑制剂；局部进展期胃癌；晚期胃癌

全文:

PDF


参考


[1]Sung H, Ferlay J, Siegel RL, et al. Global Cancer

Statistics 2020: GLOBOCAN Estimates of Incidence and

Mortality Worldwide for 36 Cancers in 185 Countries. CA

Cancer J Clin. 2021 May;71(3):209-249. DOI: 10.3322/

caac.21660.

[2]Siegel RL, Miller KD, Jemal A, et al. Cancer

statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. DOI:

10.3322/caac.21590.

[3]Ilson DH, et al. Advances in the treatment of gastric

cancer: 2020-2021. Curr Opin Gastroenterol. 2021 Nov

1;37(6):615-618. DOI: 10.1097/MOG.0000000000000776.

[4]Sexton RE, Al Hallak MN, Diab M, et al.

Gastric cancer: a comprehensive review of current and

future treatment strategies. Cancer Metastasis Rev. 2020

Dec;39(4):1179-1203. DOI: 10.1007/s10555-020-09925-3.

[5]苗儒林，李子禹，季加孚.从中国胃肠肿瘤外科

联盟相关数据分析我国早期胃癌诊治现状和发展趋势

[J].中国实用外科杂志，2019，39（05）：419-423.DOI：

10.19538/j.cjps.issn1005-2208.2019.05.03.

[6]季加孚，季科.我国胃癌外科治疗相关临床研究

近10年进展及未来方向[J].中国实用外科杂志，2022，42

（10）：1081-1083+1091.DOI：10.19538/j.cjps.issn1005-

2208.2022.10.01.

[7]Seeneevassen L, Bessède E, Mégraud F, et al.

Gastric Cancer: Advances in Carcinogenesis Research and

New Therapeutic Strategies[J]. Int J Mol Sci. 2021 Mar

26;22(7):3418. DOI: 10.3390/ijms22073418.

[8]Ishida Y, Agata Y, Shibahara K, et al. Induced

expression of PD-1, a novel member of the immunoglobulin

gene superfamily, upon programmed cell death[J]. EMBO

J. 1992 Nov;11(11):3887-95. DOI: 10.1002/j.1460-

2075.1992.tb05481.x.

[9]陈俊俊，蒋敬庭，吴昌平，等.PD-L1信号在免

疫应答中的作用及对T细胞的调控机制[J].临床检验杂

志，2012，30（06）：450-452.DOI：10.13602/j.cnki.

jcls.2012.06.002.

[10]Ahmadzadeh M, Johnson LA, Heemskerk B, et al.

Tumor antigen-specific CD8 T cells infiltrating the tumor

express high levels of PD-1 and are functionally impaired[J].

Blood. 2009 Aug 20;114(8):1537-44. DOI: 10.1182/blood-

2008-12-195792.

[11]Sanmamed MF, Chen L, et al. Inducible expression

of B7-H1 (PD-L1) and its selective role in tumor site

immune modulation[J]. Cancer J. 2014 Jul-Aug;20(4):256-

61. DOI: 10.1097/PPO.0000000000000061.

[12]Sharma P, Allison JP, et al. Immune checkpoint

targeting in cancer therapy: toward combination strategies

with curative potential[J]. Cell. 2015 Apr 9;161(2):205-14.

DOI: 10.1016/j.cell.2015.03.030.

[13]Kwa MJ, Adams S, et al. Checkpoint inhibitors in

triple-negative breast cancer (TNBC): Where to go from

here[J]. Cancer. 2018 May 15;124(10):2086-2103. DOI:

10.1002/cncr.31272.

[14]Rota G, Niogret C, Dang AT, et al. Shp-2 Is

Dispensable for Establishing T Cell Exhaustion and for PD-1

Signaling In Vivo[J]. Cell Rep. 2018 Apr 3;23(1):39-49.

DOI: 10.1016/j.celrep.2018.03.026.

[15]Sheppard KA, Fitz LJ, Lee JM, et al. PD-1

inhibits T-cell receptor induced phosphorylation of the

ZAP70/CD3zeta signalosome and downstream signaling to

PKCtheta[J]. FEBS Lett. 2004 Sep 10;574(1-3):37-41. DOI:

10.1016/j.febslet.2004.07.083.

[16]Boussiotis VA, et al. Molecular and Biochemical

Aspects of the PD-1 Checkpoint Pathway[J]. N Engl J

Med. 2016 Nov 3;375(18):1767-1778. DOI: 10.1056/

NEJMra1514296.

[17]Patsoukis N, Brown J, Petkova V, et al. Selective

effects of PD-1 on Akt and Ras pathways regulate molecular

components of the cell cycle and inhibit T cell proliferation[J].

Sci Signal. 2012 Jun 26;5(230):ra46. DOI: 10.1126/

scisignal.2002796.

[18]Chen LT, Satoh T, Ryu MH, et al. A phase 3

study of nivolumab in previously treated advanced gastric

or gastroesophageal junction cancer (ATTRACTION-2):

2-year update data[J]. Gastric Cancer. 2020 May;23(3):510-

519. DOI: 10.1007/s10120-019-01034-7.

[19]中国临床肿瘤学会指南工作委员会.中国临床肿

瘤学会（CSCO）胃癌诊疗指南[M].北京：人民卫生出

版社，2023.

[20]Muro K, Chung HC, Shankaran V, et al.

Pembrolizumab for patients with PD-L1-positive advanced

gastric cancer (KEYNOTE-012): a multicentre, open-label,

phase 1b trial[J]. Lancet Oncol. 2016 Jun;17(6):717-726.

DOI: 10.1016/S1470-2045(16)00175-3.

[21]Janjigian YY, Kawazoe A, Bai Y, et al. KEYNOTE-

811 Investigators. Pembrolizumab plus trastuzumab and

chemotherapy for HER2-positive gastric or gastrooesophageal junction adenocarcinoma: interim analyses from

the phase 3 KEYNOTE-811 randomised placebo-controlled

trial[J]. Lancet. 2023 Dec 9;402(10418):2197-2208. DOI:

10.1016/S0140-6736(23)02033-0.

[22]Rha SY, Oh DY, Yañez P, et al. KEYNOTE-

859 investigators. Pembrolizumab plus chemotherapy

versus placebo plus chemotherapy for HER2-negative

advanced gastric cancer (KEYNOTE-859): a multicentre,

randomised, double-blind, phase 3 trial[J]. Lancet Oncol.

2023 Nov;24(11):1181-1195. DOI: 10.1016/S1470-

2045(23)00515-6.

[23]许威，阎龙，杨佳兴等.PD-1抑制剂在晚期胃

癌治疗的研究进展[J].河北医药，2024，46（10）：1565-

1569[J].DOI：10.3969/j.issn.1002-7368.2024.10.028.

[24]Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase

III, randomised trial of avelumab versus physician's choice

of chemotherapy as third-line treatment of patients with

advanced gastric or gastro-oesophageal junction cancer:

primary analysis of JAVELIN Gastric 300[J]. Ann Oncol. 2018

Oct 1;29(10):2052-2060. DOI: 10.1093/annonc/mdy264.

[25]Vick SC, Kolupaev OV, Perou CM, et al. AntiPD-1 Checkpoint Therapy Can Promote the Function and

Survival of Regulatory T Cells[J]. J Immunol. 2021 Nov

15;207(10):2598-2607. DOI: 10.4049/jimmunol.2001334.

[26]Vacchelli E, Aranda F, Eggermont A, et al. Trial

Watch: Chemotherapy with immunogenic cell death

inducers[J]. Oncoimmunology. 2014 Jan 1;3(1):e27878. DOI:

10.4161/onci.27878.

[27]Boku N, Ryu MH, Kato K, et al. Safety and efficacy

of nivolumab in combination with S-1/capecitabine plus

oxaliplatin in patients with previously untreated, unresectable,

advanced, or recurrent gastric/gastroesophageal junction

cancer: interim results of a randomized, phase II trial

(ATTRACTION-4)[J]. Ann Oncol. 2019 Feb 1;30(2):250-

258. DOI: 10.1093/annonc/mdy540.

[28]Janjigian YY, Shitara K, Moehler M, et al. Firstline nivolumab plus chemotherapy versus chemotherapy

alone for advanced gastric, gastro-oesophageal junction,

and oesophageal adenocarcinoma (CheckMate 649):

a randomised, open-label, phase 3 trial[J]. Lancet.

2021 Jul 3;398(10294):27-40. DOI: 10.1016/S0140-

6736(21)00797-2. Epub 2021 Jun 5.

[29]Sun YT, Lu SX, Lai MY, et al. Clinical outcomes

and biomarker exploration of first-line PD-1 inhibitors

plus chemotherapy in patients with low PD-L1-expressing

of gastric or gastroesophageal junction adenocarcinoma[J].

Cancer Immunol Immunother. 2024 Jun 4;73(8):144. DOI:

10.1007/s00262-024-03721-6.

[30]Zhao JJ, Yap DWT, Chan YH, et al. Low

Programmed Death-Ligand 1-Expressing Subgroup

Outcomes of First-Line Immune Checkpoint Inhibitors in

Gastric or Esophageal Adenocarcinoma[J]. J Clin Oncol. 2022

Feb 1;40(4):392-402. DOI: 10.1200/JCO.21.01862.

[31]Liu T, Bai Y, Lin X, et al. First-line nivolumab

plus chemotherapy vs chemotherapy in patients with

advanced gastric, gastroesophageal junction and esophageal

adenocarcinoma: CheckMate 649 Chinese subgroup

analysis[J]. Int J Cancer. 2023 Feb 15;152(4):749-760. DOI:

10.1002/ijc.34296. Epub 2022 Oct 31.

[32]Ren S, Xiong X, You H, et al. The Combination of

Immune Checkpoint Blockade and Angiogenesis Inhibitors in

the Treatment of Advanced Non-Small Cell Lung Cancer[J].

Front Immunol. 2021 Jun 2;12:689132. DOI: 10.3389/

fimmu.2021.689132.

[33]Terme M, Pernot S, Marcheteau E, et al. VEGFA-

VEGFR pathway blockade inhibits tumor-induced regulatory

T-cell proliferation in colorectal cancer[J]. Cancer Res. 2013

Jan 15;73(2):539-49. DOI: 10.1158/0008-5472.CAN-12-

2325.

[34]Wilke H, et al. Ramucirumab plus paclitaxel

versus placebo plus paclitaxel in patients with previously

treated advanced gastric or gastro-oesophageal junction

adenocarcinoma (RAINBOW): a double-blind, randomised

phase 3 trial[J]. Lancet Oncol. 2014;15:1224–1235.

DOI: 10.1016/S1470-2045(14)70420-6.

[35]Li J, et al. Randomized, Double-Blind, PlaceboControlled Phase III Trial of Apatinib in Patients With

Chemotherapy-Refractory Advanced or Metastatic

Adenocarcinoma of the Stomach or Gastroesophageal

Junction[J]. J. Clin. Oncol. 2016;34:1448–1454.

DOI: 10.1200/JCO.2015.63.5995.

[36]Li S, Yu W, Xie F, et al. Neoadjuvant therapy

with immune checkpoint blockade, antiangiogenesis, and

chemotherapy for locally advanced gastric cancer[J]. Nat

Commun. 2023 Jan 3;14(1):8. DOI: 10.1038/s41467-022-

35431-x.

[37]Peng Z, Wei J, Wang F, et al. Camrelizumab

Combined with Chemotherapy Followed by Camrelizumab

plus Apatinib as First-line Therapy for Advanced Gastric or

Gastroesophageal Junction Adenocarcinoma[J]. Clin Cancer

Res. 2021 Jun 1;27(11):3069-3078. DOI: 10.1158/1078-

0432.CCR-20-4691.

[38]Lee J, Bass AJ, Ajani JA, et al. Gastric

Adenocarcinoma: An Update on Genomics, Immune System

Modulations, and Targeted Therapy[J]. Am Soc Clin Oncol

Educ Book. 2016;35:104-11. DOI: 10.1200/EDBK_159091.

[39]Wang Y, He L, Cheng Y, et al. An independent

survival prognostic role for human epidermal growth factor

receptor 2 in gastric cancer: evidence from a meta-analysis[J].

Clin Transl Oncol. 2018 Feb;20(2):212-220. DOI: 10.1007/

s12094-017-1711-5.

[40]Chaganty BKR, Qiu S, Gest A, et al. Trastuzumab

upregulates PD-L1 as a potential mechanism of trastuzumab

resistance through engagement of immune effector cells and

stimulation of IFNγ secretion[J]. Cancer Lett. 2018 Aug

28;430:47-56. DOI: 10.1016/j.canlet.2018.05.009.

[41]Janjigian YY, Maron SB, Chatila WK,et al. Firstline pembrolizumab and trastuzumab in HER2-positive

oesophageal, gastric, or gastro-oesophageal junction

cancer: an open-label, single-arm, phase 2 trial[J]. Lancet

Oncol. 2020 Jun;21(6):821-831. DOI: 10.1016/S1470-

2045(20)30169-8. Epub 2020 May 18.

[42] Janjigian Y.Y, Kawazoe A, Yanez P.E,et al.

Pembrolizumab plus trastuzumab and chemotherapy for

HER2+ metastatic gastric or gastroesophageal junction

(G/GEJ) Cancer: Initial findings of the global phase 3

KEYNOTE-811 study[J]. J. Clin. Oncol. 2021;39:4013.

DOI: 10.1200/JCO.2021.39.15_suppl.4013.

[43]Tao KX, Yin YP, Lin Y, et al. Neoadjuvant PD- 1

inhibitor tislelizumab combined with s- 1 plus oxaliplatin in

patients with local advanced gastric cancer or gastroesophageal

junction adenocarcinoma：interim results of a single-arm，

phase Ⅱ trial[J]. J Clin Oncol，2022，40（4_suppl）：300.

DOI:10.1200/JCO.2022.40.4_suppl. 300.

[44]Xie BW, Zang L, Ma JJ, Sun J, Yang X, Wang

ML, et al. [Safety and effectiveness of oxaliplatin combined

with capecitabine or oxaliplatin combined with s-1

neoadjuvant chemotherapy in the treatment of advanced

gastric cancer[J]. Zhonghua Wei Chang Wai Ke Za

Zhi. (2021) 24(2):138–44. DOI: 10.3760/cma.j.cn.441530-

20200721-00433

[45]Ding X，Li B，Xue Q, et al. Perioperative

sintilimab combination with SOX for resectable locally

advanced gastric/gastroesophageal junction cancer(GC/

GEJC): Initial findings of a single-arm phase II trial [J]. J Clin

Oncol，2022，40(suppl 4):294.

[46]Yin Y, Lin Y, Yang M, et al. Neoadjuvant

tislelizumab and tegafur/gimeracil/octeracil (S-1) plus

oxaliplatin in patients with locally advanced gastric or

gastroesophageal junction cancer: Early results of a phase 2,

single-arm trial[J]. Front Oncol. 2022 Aug 30;12:959295.

DOI: 10.3389/fonc.2022.959295.

[47]Tang Z, Wang Y, Liu D, et al. The Neo-PLANET

phase II trial of neoadjuvant camrelizumab plus concurrent

chemoradiotherapy in locally advanced adenocarcinoma of

stomach or gastroesophageal junction[J]. Nat Commun. 2022

Nov 10;13(1):6807. DOI: 10.1038/s41467-022-34403-5.

[48]Chuang E, Fisher TS, Morgan RW, et al. The CD28

and CTLA-4 receptors associate with the serine/threonine

phosphatase PP2A[J]. Immunity. 2000 Sep;13(3):313-22.

DOI: 10.1016/s1074-7613(00)00031-5. PMID: 11021529.

[49]Stein PH, Fraser JD, Weiss A, et al. The cytoplasmic

domain of CD28 is both necessary and sufficient for

costimulation of interleukin-2 secretion and association

with phosphatidylinositol 3'-kinase[J]. Mol Cell Biol. 1994

May;14(5):3392-402. DOI: 10.1128/mcb.14.5.3392-

3402.1994.

[50]Walunas TL, Lenschow DJ, Bakker CY, et al.

CTLA-4 can function as a negative regulator of T cell

activation[J]. Immunity. 1994 Aug;1(5):405-13. DOI:

10.1016/1074-7613(94)90071-x.

[51]Linsley PS, Bradshaw J, Greene J, et al. Intracellular

trafficking of CTLA-4 and focal localization towards sites of

TCR engagement[J]. Immunity. 1996 Jun;4(6):535-43. DOI:

10.1016/s1074-7613(00)80480-x.

[52]Chuang E, Alegre ML, Duckett CS, et al.

Interaction of CTLA-4 with the clathrin-associated protein

AP50 results in ligand-independent endocytosis that limits

cell surface expression[J]. J Immunol. 1997 Jul 1;159(1):144-

51.DOI:org/10.4049/jimmunol.159.1.144.

[53]Azuma M, Ito D, Yagita H, et al. B70 antigen is a

second ligand for CTLA-4 and CD28[J]. Nature. 1993 Nov

4;366(6450):76-9. DOI: 10.1038/366076a0.

[54]Krummel MF, Allison JP, et al. CTLA-4

engagement inhibits IL-2 accumulation and cell cycle

progression upon activation of resting T cells[J]. J Exp Med.

1996 Jun 1;183(6):2533-40. DOI: 10.1084/jem.183.6.2533.

[55]McDermott D, Haanen J, Chen TT, et al. Efficacy

and safety of ipilimumab in metastatic melanoma patients

surviving more than 2 years following treatment in a phase III

trial (MDX010-20)[J]. Ann Oncol. 2013 Oct;24(10):2694-

2698. DOI: 10.1093/annonc/mdt291.

[56]Bang YJ, Cho JY, Kim YH, et al. Efficacy of

Sequential Ipilimumab Monotherapy versus Best Supportive

Care for Unresectable Locally Advanced/Metastatic Gastric or

Gastroesophageal Junction Cancer[J]. Clin Cancer Res. 2017

Oct 1;23(19):5671-5678. DOI: 10.1158/1078-0432.CCR-

17-0025.

[57]Ralph C, Elkord E, Burt DJ, et al. Modulation

of lymphocyte regulation for cancer therapy: a phase II

trial of tremelimumab in advanced gastric and esophageal

adenocarcinoma[J]. Clin Cancer Res. 2010 Mar 1;16(5):1662-

72. DOI: 10.1158/1078-0432.CCR-09-2870.

[58]Felix J, Lambert J, Roelens M, et al. Ipilimumab

reshapes T cell memory subsets in melanoma patients

with clinical response[J]. Oncoimmunology. 2016 Feb

18;5(7):1136045. DOI: 10.1080/2162402X.2015.1136045.

[59]Rotte A, et al. Combination of CTLA-4 and PD-1

blockers for treatment of cancer[J]. J Exp Clin Cancer Res.

2019 Jun 13;38(1):255. DOI: 10.1186/s13046-019-1259-z.

[60]Janjigian YY, Bendell J, Calvo E, et al. CheckMate-

032 Study: Efficacy and Safety of Nivolumab and Nivolumab

Plus Ipilimumab in Patients With Metastatic Esophagogastric

Cancer[J]. J Clin Oncol. 2018 Oct 1;36(28):2836-2844. DOI:

10.1200/JCO.2017.76.6212.

[61]Janjigian YY, Shitara K, Moehler M, et al. Firstline nivolumab plus chemotherapy versus chemotherapy

alone for advanced gastric, gastro-oesophageal junction, and

oesophageal adenocarcinoma (CheckMate 649): a randomised,

open-label, phase 3 trial. Lancet. 2021 Jul 3;398(10294):27-

40. DOI: 10.1016/S0140-6736(21)00797-2.

[62]Raimondi A, Palermo F, Prisciandaro M, et al.

TremelImumab and Durvalumab Combination for the NonOperatIve Management (NOM) of Microsatellite InstabiliTY

(MSI)-High Resectable Gastric or Gastroesophageal Junction

Cancer: The Multicentre, Single-Arm, Multi-Cohort,

Phase II INFINITY Study[J]. Cancers (Basel). 2021 Jun

7;13(11):2839. DOI: 10.3390/cancers13112839.

[63]Jiafu Ji, Lin Shen, Ziyu Li, et al.A phase Ib/II,

multicenter, open-label study of AK104, a PD-1/CTLA-4

bispecific antibody, combined with chemotherapy (chemo) as

first-line therapy for advanced gastric (G) or gastroesophageal

junction (GEJ) cancer: 2-Year update data[J]. 2023 ASCO

Annual Meeting. DOI.org/10.1200/JCO.2023.41.16_

suppl.4031.

[64]Gao X, Wu X, Ji J, et al. Safety and antitumour

activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific

antibody, for patients with advanced solid tumours

(COMPASSION-03): a multicentre, open-label, phase 1b/2

trial[J]. Lancet Oncol. 2023 Oct, DOI: 10.1016/S1470-

2045(23)00411-4.

[65]Mukherjee S, Parmar K, Smyth E, et al. Immune

checkpoint inhibitors in resectable gastroesophageal cancers

- a review[J]. Ther Adv Med Oncol. 2022 Nov , DOI:

10.1177/17588359221139625.


Refbacks

  • 当前没有refback。